HLA DRA Antibody (19-26.1 (same as MB-26.1)), Novus Biologicals™

HLA DRA

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), SDS-Page, Immunofluorescence

Unconjugated

Mouse

Adaptive Immunity, Cell Biology, Diabetes Research, Immunology

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

3122

Raji Cells

Primary

Store at 4C.

19-26.1 (same as MB-26.1)

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 1 - 2 ug/ml, SDS-Page, Immunofluorescence 0.5 - 1.0 ug/ml

Monoclonal

Purified

RUO

Human

FLJ51114, histocompatibility antigen HLA-DR alpha, HLA class II histocompatibility antigen, DR alpha chain, HLA-DRA1, major histocompatibility complex, class II, DR alpha, MHC cell surface glycoprotein, MHC class II antigen DRA, MLRW

HLA-DRA

IgG2a κ

Protein A or G purified

This MAb reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. It is an excellent histiocytic marker in paraffin sections producing intense cytoplasmic staining. True histiocytic neoplasms are similarly positive. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.